Spero Q2 FY26 net loss widens to $9.6 million; revenue posts no revenue

• Spero Therapeutics posted a Q2 net loss of $9.6 million, widening from a $1.7 million loss a year earlier; loss per share widened to $0.16.
• Revenue was nil, versus $14.2 million in the prior-year quarter.
• R&D expense fell to $3.4 million from $10.7 million, due to lower Utebzi Phase 3 activity and reduced personnel costs.
• G&A expense rose to $6.5 million from $5.9 million, on higher legal and business development costs.
• Cash totaled $50.8 million at June 30; $105 million royalty financing extends runway into the second half of 2029.
• FDA cleared Utebzi for adult cUTIs; GSK expects U.S. availability by end-2026.
• Licensed Phase 2-ready SP001 from Innovent outside Greater China; plans a Phase 2 study in IgG4-related disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121601PRIMZONEFULLFEED9808841) on August 12, 2026, and is solely responsible for the information contained therein.